Legendary rock guitarist Mark Kendall shocked the music world when he announced back in November that he was battling stage 4 kidney cancer, and he recently opened up more about his fight. Kendall ...

The American Cancer Society has released its annual report on cancer in America. According to the newly released data, the 5-year cancer survival rate in the United States has reached a milestone mark ...

Mark & Bridges Technology, a Brazilian multinational IT services consulting firm, has partnered with Magic Software Brasil to offer projects for the development of vertical AI agents, focusing on ...

When Lisa Dutton was declared free of breast cancer in 2017, she took a moment to celebrate with family and friends, even though she knew her cancer journey might not be over. As many as one-third of ...

Yahoo College & High School Sports is powered by On3, delivering expert recruiting, NIL, and transfer portal news. Daigneault commended Topic’s approach amid cancer treatment, he said, per Thunder ...

Oklahoma City Thunder head coach Mark Daigneault offered an update on Nikola Topic after the rookie participated in pregame shootaround before the previous two home games at the Paycom Center, ...

Former Sen. Ben Sasse, R-Neb., announced Tuesday that he has been diagnosed with "metastasized, stage-four pancreatic cancer," writing in an X post that the diagnosis is "a death sentence." "Last week ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer.

Mark Cuban Cost Plus Drug Co. has added Vegzelma, a biosimilar indicated for six cancer types, to its marketplace for hospitals and other healthcare providers. The company plans to expand its ...

Editor’s note: The following story was submitted for the Shaler Area Student Section, a collaboration between TribLive and The Oracle, the student newspaper of Shaler Area High School. Usually a visit ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first treatment after endocrine therapy for ...

The antibody-drug conjugate sacituzumab govitecan (Trodelvy) did not improve progression-free survival among patients with endocrine-refractory hormone receptor (HR)+/HER2- advanced breast cancer when ...